Skip to content

ASRS '26: SOL-1 and TRUCKEE at 4.5 Years

August 5, 2026 · 24 min

Show notes

Could TKIs be the game-changing therapy that makes wet AMD treatment less burdensome? Dilsher Dhoot, MD, joins the show to examine the SOL-1 study, a superiority study assessing the safety, efficacy, and durability of axitinib (Axpaxli, Ocular Therapeutix) for the treatment of wet AMD.


And Carl Danzig, MD, stops by to deliver the 4.5-year data from TRUCKEE, which tells us how real-world patients with wet AMD perform when dosed with faricimab (Vabysmo, Genentech/Roche). How are patients doing after 3, 6, or even 9 doses? Stick with us to find out.

All episodes of New Retina Radio by Eyetube

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.